Matthew F Daley, Sheryl L Rifas-Shiman, Jessica G Young, Joshua Petimar, Carly Prentice, L Charles Bailey, David M Janicke, William J Heerman, Jason P Block
{"title":"Effects of Common Antihypertensive Class Medications on BMI z-Score in Adolescents.","authors":"Matthew F Daley, Sheryl L Rifas-Shiman, Jessica G Young, Joshua Petimar, Carly Prentice, L Charles Bailey, David M Janicke, William J Heerman, Jason P Block","doi":"10.1111/ijpo.70114","DOIUrl":"10.1111/ijpo.70114","url":null,"abstract":"<p><strong>Background: </strong>Antihypertensive class medications are prescribed long-term for adolescents, including for conditions other than hypertension. Evidence on weight effects is limited.</p><p><strong>Objective: </strong>To assess the weight effects of commonly prescribed antihypertensive class medications among adolescents, regardless of clinical indication for use.</p><p><strong>Methods: </strong>This retrospective study was conducted using electronic health record (EHR) data from a multi-site US research network. The study cohort included adolescents aged 13.0-19.5 years with ≥ 1 antihypertensive class medication order during 2010-2019. Weight and height documented in the EHR were used to calculate BMI z-scores. Inverse probability weighting with marginal structural models was used to account for selection factors and covariates.</p><p><strong>Results: </strong>Overall, 23 853 adolescents were prescribed an antihypertensive class medication, including clonidine (prescribed to n = 7491), guanfacine (n = 6411), lisinopril (n = 3584), propranolol (n = 3015), spironolactone (n = 1926), and atenolol (n = 1426). At baseline, 13% had a hypertension diagnosis. At 12 months after medication initiation, the estimated population-level BMI z-score was significantly increased for propranolol (BMI z-score 0.19 [95% CI 0.09, 0.29]) and significantly decreased for lisinopril (-0.06 [95% CI -0.10, -0.01]); clonidine, guanfacine, spironolactone, and atenolol were not associated with a significant change in BMI z-score.</p><p><strong>Conclusions: </strong>Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.</p>","PeriodicalId":217,"journal":{"name":"Pediatric Obesity","volume":"21 5","pages":"e70114"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147979694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Continuous Glucose Monitoring Metrics Are Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease and Not Dysglycaemia in Adolescents With Obesity-A Pilot Study.","authors":"Alapan Mahapatra, Manoj Agarwal, Vibha Yadav, Prashant Shukla, Anoop Misra, Anurag Bajpai","doi":"10.1111/ijpo.70110","DOIUrl":"10.1111/ijpo.70110","url":null,"abstract":"<p><strong>Introduction: </strong>The clinical relevance of continuous glucose monitoring (CGM) metrics in adolescents with obesity remains uncertain, particularly in relation to obesity-related metabolic comorbidities.</p><p><strong>Methods: </strong>In a pilot study, 39 adolescents with obesity (age 12.9 ± 2.9 years); 29 boys; mean body mass index standard deviation score (BMI SDS; 2.25 ± 0.58) underwent 15 days of CGM along with fasting plasma glucose, oral glucose tolerance testing (OGTT), glycated haemoglobin (HbA1c), and assessment of metabolic comorbidities.</p><p><strong>Results: </strong>Adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD; n = 5, 12.8%) demonstrated higher median mean amplitude of glycaemic excursion (MAGE; 42.4 vs. 35.2 mg/dL; p = 0.019) and mean of daily difference (MODD; 23.3 vs. 18.5 mg/dL; p = 0.062) compared with those without it. BMI SDS correlated positively with glucose management indicator (GMI; ρ = 0.34, p = 0.041), mean glucose (ρ = 0.34, p = 0.041), and continuous overall net glycaemic action (CONGA; ρ = 0.38, p = 0.022), whereas fasting glucose, 2-h OGTT glucose, and HbA1c showed no associations.</p><p><strong>Conclusions: </strong>In adolescents with obesity, CGM-derived glycaemic variability metrics were associated with adiposity and MASLD, whereas conventional laboratory measures were not. These findings suggest that CGM may provide complementary information for metabolic phenotyping in paediatric obesity. Longitudinal studies are required to determine implications.</p>","PeriodicalId":217,"journal":{"name":"Pediatric Obesity","volume":"21 5","pages":"e70110"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
